Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer

Oncology
S BoeckV Heinemann

Abstract

To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients. Within a prospective single-center study, Cap was offered to patients who had already received at least 1 previous treatment regimen containing full-dose Gem (as a single agent, as part of a combination chemotherapy regimen or sequentially within a chemoradiotherapy protocol). Cap was administered orally at a dose of 1,250 mg/m(2) twice daily for 14 days followed by 7 days of rest. Study endpoints were objective tumor response rate by imaging criteria (according to RECIST), carbohydrate antigen 19-9 (CA19-9) tumor marker response, time to progression, overall survival and toxicity. A median of 3 treatment cycles (range 1-36) was given to 39 patients. After a median follow-up of 6.6 months, 27 patients were evaluable for response: no complete or partial responses were observed, but 15 patients (39%) had stable disease. A CA19-9 reduction of >20% after 2 cycles of Cap was documented in 6 patients (15%). Median time to progression was 2.3 months (range 0.5-45.1) and median overa...Continue Reading

Associated Clinical Trials

Citations

May 19, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Michael HaasStefan Boeck
Jan 17, 2012·Industrial & Engineering Chemistry Research·Cody A SchoenerNicholas A Peppas
Mar 2, 2010·Japanese Journal of Clinical Oncology·Akiko TodakaHideharu Tomita
May 14, 2010·Japanese Journal of Clinical Oncology·Yousuke NakaiKazuhiko Koike
Mar 1, 2010·Therapeutic Advances in Medical Oncology·Ben Lawrence, Michael Findlay
Sep 13, 2012·World Journal of Gastroenterology : WJG·Carmen BelliMichele Reni
Feb 25, 2014·Cancer Chemotherapy and Pharmacology·Heloisa P SoaresCaio M Rocha-Lima
Jan 20, 2009·Cancer Chemotherapy and Pharmacology·Margherita NanniniGuido Biasco
Mar 8, 2014·World Journal of Gastroenterology : WJG·Evan J Walker, Andrew H Ko
Dec 19, 2012·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Katharina Elisabeth Tschoep-LechnerRolf-Dieter Issels
Sep 2, 2015·Expert Review of Anticancer Therapy·Concetta Elisa OnestiPaolo Marchetti
Dec 12, 2012·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Sheng-bin ShiQuan-yun Liu
Jan 23, 2010·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·M Wasif SaifY-C Cheng
Sep 18, 2009·Cancer Treatment Reviews·Ana CustodioEduardo Díaz-Rubio
Dec 17, 2015·Cancer Chemotherapy and Pharmacology·Carmen BelliMichele Reni
Jan 3, 2013·Journal of Biomedical Materials Research. Part a·Cody A SchoenerNicholas A Peppas
Apr 5, 2016·Expert Review of Anticancer Therapy·Sana Saif Ur RehmanAndrea Wang-Gillam
Apr 27, 2011·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Jeong Youp Park
Mar 11, 2015·Therapeutic Advances in Medical Oncology·Andrea TeagueAndrea Wang-Gillam
Apr 19, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·L Gutierrez-SainzJ Feliu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Matthew H KulkeCharles S Fuchs
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Thomas H CartwrightJoseph J Schulz
Japanese Journal of Clinical Oncology
Kohei NakachiMasahiro Yoshino
© 2022 Meta ULC. All rights reserved